MBA of McGill University
Joining Winhealth in Jan 2019, Mr. Hao brought a wide spectrum of experience and skill sets including strategic innovation, business development, model upgrades, business incubation of rare deseases.
Previously, he served as SVP of strategic development, GM for B2B business at 111 Inc. (NASDAQ: YI), building the nation-wide B2B pharmacy platform from 0 to 1 and participated in the company's IPO in 2018.
Prior to that, he served as the Co-CEO of Sinco Pharm (Hong Kong: 06833), VP and GM of the pharmaceutical business, Finance Director in China for Cardinal Health (NYSE: CAH). He is also a major participant and supported Cardinal Health's USD 470 mln acquisition of Zuellig Pharma in 2010.
He served as the Executive Director of Finance of Eli Lilly in Canada, and the Director of Financial Planning and Procurement for Eli Lilly in China.